0
GlycoMimetics Banner Image

GlycoMimetics

  • Ticker GLYC
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
GlycoMimetics Logo Image
  • 51-200 Employees
  • Based in Rockville, Maryland
GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cellMore disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also completed a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region.
REPORT RATINGS
4.8 / 5.0 (196)

GlycoMimetics reports have an aggregate usefulness score of 4.8 based on 196 reviews.

GlycoMimetics

Most Recent Annual Report

GlycoMimetics
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

GlycoMimetics Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!